41 related articles for article (PubMed ID: 9010106)
1. External validation of biochemical recurrence definition to predict oncologic outcomes following focal therapy for localized prostate cancer using high intensity focused ultrasound.
Mattlet A; Limani K; Alexandre P; Hawaux E; Abou Zahr R; Aoun F; Diamand R
Prostate; 2023 Dec; 83(16):1564-1571. PubMed ID: 37574824
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients.
Lin GW; Yao XD; Zhang SL; Dai B; Ma CG; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Shi GH; Qin XJ; Ye DW
Asian J Androl; 2009 Jul; 11(4):443-50. PubMed ID: 19182820
[TBL] [Abstract][Full Text] [Related]
3. Remission Depth in Metastatic Hormone-Sensitive Prostate Cancer Is Associated With Prognosis in Patients With Initial Prostate-Specific Antigen Values Above 100 Ng/ML.
Azuma T; Katsumata A; Kano M; Tsumura K
Cureus; 2024 Feb; 16(2):e54036. PubMed ID: 38481910
[TBL] [Abstract][Full Text] [Related]
4. Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real-world setting of metastatic hormone-sensitive prostate cancer patients.
Wenzel M; Hoeh B; Hurst F; Koll F; Cano Garcia C; Humke C; Steuber T; Tilki D; Traumann M; Banek S; Chun FKH; Mandel P
Prostate; 2024 May; ():. PubMed ID: 38812332
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Outcomes After Abdominal Radiation for Wilms Tumor: A 20-Year Experience.
Conte B; Shen C; Thompson P; Davis I; Casey DL
Am J Clin Oncol; 2024 Mar; 47(3):128-131. PubMed ID: 38088232
[TBL] [Abstract][Full Text] [Related]
6. Prostate-Specific Antigen Nadir Postradiotherapy in Localized Prostate Cancer: Is It Prognostic or Predictive?
Spratt DE
J Clin Oncol; 2024 May; ():JCO2302689. PubMed ID: 38743913
[No Abstract] [Full Text] [Related]
7. The history of cryosurgery in Canada: A tale of two cities.
Chin JL; Donnelly BJ; Nair SM; Lavi A
Can Urol Assoc J; 2020 Oct; 14(10):299-304. PubMed ID: 32569572
[TBL] [Abstract][Full Text] [Related]
8. Current approaches, challenges and future directions for monitoring treatment response in prostate cancer.
Wallace TJ; Torre T; Grob M; Yu J; Avital I; Brücher B; Stojadinovic A; Man YG
J Cancer; 2014 Jan; 5(1):3-24. PubMed ID: 24396494
[TBL] [Abstract][Full Text] [Related]
9. PSA Doubling Time Predicts for the Development of Distant Metastases for Patients Who Fail 3DCRT Or IMRT Using the Phoenix Definition.
Klayton TL; Ruth K; Buyyounouski MK; Uzzo RG; Wong YN; Chen DY; Sobczak M; Peter R; Horwitz EM
Pract Radiat Oncol; 2011; 1(4):235-242. PubMed ID: 22025934
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death.
Alcantara P; Hanlon A; Buyyounouski MK; Horwitz EM; Pollack A
Cancer; 2007 Jan; 109(1):41-7. PubMed ID: 17133416
[TBL] [Abstract][Full Text] [Related]
11. Radiation therapy failure in prostate cancer patients: risk factors and methods of detection.
Brawer MK
Rev Urol; 2002; 4 Suppl 2(Suppl 2):S2-S11. PubMed ID: 16986008
[TBL] [Abstract][Full Text] [Related]
12. Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer.
Pound CR; Brawer MK; Partin AW
Rev Urol; 2001; 3(2):72-84. PubMed ID: 16985694
[TBL] [Abstract][Full Text] [Related]
13. Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?
Canby-Hagino ED; Swanson GP; Crawford ED; Basler JW; Hernandez J; Thompson IM
Curr Urol Rep; 2005 May; 6(3):183-9. PubMed ID: 15869722
[TBL] [Abstract][Full Text] [Related]
14. Localized prostate cancer: early intervention or expectant therapy?
Griffiths TR; Neal DE
J R Soc Med; 1997 Dec; 90(12):665-9. PubMed ID: 9496291
[No Abstract] [Full Text] [Related]
15. Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen.
Crook JM; Bahadur YA; Bociek RG; Perry GA; Robertson SJ; Esche BA
Cancer; 1997 Jan; 79(2):328-36. PubMed ID: 9010106
[TBL] [Abstract][Full Text] [Related]
16. Serum prostate-specific antigen profile following radiotherapy for prostate cancer: implications for patterns of failure and definition of cure.
Crook JM; Choan E; Perry GA; Robertson S; Esche BA
Urology; 1998 Apr; 51(4):566-72. PubMed ID: 9586608
[TBL] [Abstract][Full Text] [Related]
17. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
[TBL] [Abstract][Full Text] [Related]
18. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients.
Crook J; Malone S; Perry G; Bahadur Y; Robertson S; Abdolell M
Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):355-67. PubMed ID: 10974448
[TBL] [Abstract][Full Text] [Related]
19. Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients.
Crook JM; Perry GA; Robertson S; Esche BA
Urology; 1995 Apr; 45(4):624-31; discussion 631-2. PubMed ID: 7716843
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
